Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/11000/38409
Antagonistic Effects of BACE1 and APH1B-gSecretase Control Axonal Guidance by Regulating Growth Cone Collapse
Título : Antagonistic Effects of BACE1 and APH1B-gSecretase Control Axonal Guidance by Regulating Growth Cone Collapse |
Autor : Barao, Soraia  Gartner, Annette Leyva-Díaz, Eduardo  Demyanenko, Galina Munck, Sebastian  Vanhoutvin, Tine  Zhou, Lujia  Schachner, Melitta  López-Bendito, Guillermina  Maness, Patricia F De Strooper, Bart  |
Editor : Cell Press |
Fecha de publicación: 2015-09 |
URI : https://hdl.handle.net/11000/38409 |
Resumen :
ΒACE1 is the major drug target for Alzheimer's disease, but we know surprisingly little about its normal function in the CNS. Here, we show that this protease is critically involved in semaphorin 3A (Sema3A)-mediated axonal guidance processes in thalamic and hippocampal neurons. An active membrane-bound proteolytic CHL1 fragment is generated by BACE1 upon Sema3A binding. This fragment relays the Sema3A signal via ezrin-radixin-moesin (ERM) proteins to the neuronal cytoskeleton. APH1B-γ-secretase-mediated degradation of this fragment stops the Sema3A-induced collapse and sensitizes the growth cone for the next axonal guidance cue. Thus, we reveal a cycle of proteolytic activity underlying growth cone collapse and restoration used by axons to find their correct trajectory in the brain. Our data also suggest that BACE1 and γ-secretase inhibition have physiologically opposite effects in this process, supporting the idea that combination therapy might attenuate some of the side effects associated with these drugs.
|
Palabras clave/Materias: BACE1 alzheimer's disease APH1B axonal guidance |
Tipo de documento : info:eu-repo/semantics/article |
Derechos de acceso: info:eu-repo/semantics/openAccess Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
DOI : 10.1016/j.celrep.2015.07.059 |
Publicado en: Cell Rep . 2015 Sep 1;12(9):1367-76 |
Aparece en las colecciones: Instituto de Neurociencias
|
La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.